Lutetium-177-PSMA-617: A Vision of the Future

References

• Francini E, Gray KP, Shaw GK, Evan CP, Hamid AA, Perry CE, Kantoff PW, Taplin M-E, Sweeney CJ. 2019. Impact of new systemic therapies on overall survival of patients with metastatic castration-resistant prostate cancer in a hospital-based registry. Prostate Cancer Prostatic Dis. 22(3):420–427. 10.1038/s41391-018-0121-2.
   PubMed Web of Science ®Google Scholar
• Sandhu S, Moore CM, Chiong E, Beltran H, Bristow RG, Williams SG. 2021. Prostate cancer. The Lancet. 398(10305):1075–1090. 10.1016/s0140-6736(21)00950-8.
   PubMed Web of Science ®Google Scholar
• Feuerecker B, Tauber R, Knorr K, Heck M, Beheshti A, Seidl C, Bruchertseifer F, Pickhard A, Gafita A, Kratochwil C, et al. 2021. Activity and Adverse Events of Actinium-225-PSMA-617 in Advanced Metastatic Castration-resistant Prostate Cancer After Failure of Lutetium-177-PSMA. Eur Urol. 79(3):343–350. DOI:10.1016/j.eururo.2020.11.013
   PubMed Web of Science ®Google Scholar
• Heck MM, Retz M, Tauber R, Knorr K, Kratochwil C, Eiber M. 2017. Radionuklidtherapie des Prostatakarzinoms mittels PSMA-Lutetium. Der Urologe. 56(1):32–39. 10.1007/s00120-016-0274-3.
   Google Scholar
• Satapathy S, Sood A, Das CK, Mittal BR. 2021. Evolving role of 225Ac-PSMA radioligand therapy in metastatic castration-resistant prostate cancer—a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 24(3):880–890. 10.1038/s41391-021-00349-w.
   PubMed Web of Science ®Google Scholar
• van Kalmthout Lwm, van der Sar Eca, Braat AJAT, de Keizer B, Lam MGEH, Ajat B, van der Sar ECA, Mgeh L. Lutetium-177-PSMA therapy for prostate cancer patients—a brief overview of the literature. Tijdschrift voor Urologie. 2020;10(6–7):141–146. doi:10.1007/s13629-020-00300-z.
   Google Scholar
• Sartor O, De Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, Tagawa ST, Nordquist LT, Vaishampayan N, El-Haddad G, et al. 2021. Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. New Engl J Med. 385(12):1091–1103. DOI:10.1056/nejmoa2107322
   PubMed Web of Science ®Google Scholar
• Novartis AG. Novartis receives FDA Breakthrough Therapy designation for investigational 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer (mCRPC). Switzerland [accessed 2021 Aug 12] https://www.novartis.com/news/novartis-receives-fda-breakthrough-therapy-designation-investigational-177lu-psma-617-patients-metastatic-castration-resistant-prostate-cancer-mcrpc#:~:text=Novartis%20announced%20today%20that%20the,resistant%20prostate%20cancer%20(mCRPC).
   Google Scholar
• Hofman MS, Violet J, Hicks RJ, Ferdinandus J, Thang SP, Akhurst T, Iravani A, Kong G, Ravi Kumar A, Murphy DG, et al. 2018. [(177)Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol. 19(6):825–833. DOI:10.1016/s1470-2045(18)30198-0
   PubMed Web of Science ®Google Scholar
• Hofman MS, Emmett L, Sandhu S, Iravani A, Joshua AM, Goh JC, Pattison DA, Tan TH, Kirkwood ID, Ng S, et al. 2021. [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. The Lancet. 397(10276):797–804. DOI:10.1016/s0140-6736(21)00237-3
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Xofigo. Amsterdam (The Netherlands) [accessed 2021 Sep 01] https://www.ema.europa.eu/en/medicines/human/EPAR/xofigo
   Google Scholar
• Rahbar K, Ahmadzadehfar H, Kratochwil C, Haberkorn U, Schäfers M, Essler M, Baum RP, Kulkarni HR, Schmidt M, Drzezga A, et al. 2017. German Multicenter Study Investigating 177 Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients. J Nucl Med. 58(1):85–90. DOI:10.2967/jnumed.116.183194
   PubMed Web of Science ®Google Scholar
• Hope TA, Ahmadzadehfar H, Kratochwil C, Haberkorn U, Schäfers M, Essler M, Baum RP, Kulkarni HR, Schmidt M, Drzezga A. German Multicenter Study Investigating177 Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients”. J Nucl Med. 2017;58(1):85–90. doi:10.2967/jnumed.120.252122. Journal of Nuclear Medicine 2020; 61:255S-62S.
   PubMed Web of Science ®Google Scholar
• Afshar-Oromieh A, Hetzheim H, Kratochwil C, Benesova M, Eder M, Neels OC, Eisenhut M, Kübler W, Holland-Letz T, Giesel FL, et al. 2015. The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions. J Nucl Med. 56(11):1697–1705. DOI:10.2967/jnumed.115.161299
   PubMed Web of Science ®Google Scholar
• De Wit R, De Bono J, Sternberg CN, Fizazi K, Tombal B, Wülfing C, Kramer G, Eymard J-C, Bamias A, Carles J, et al. 2019. Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer. New Engl J Med. 381(26):2506–2518. DOI:10.1056/nejmoa1911206
   PubMed Web of Science ®Google Scholar
• Iravani A, Violet J, Azad A, Hofman MS. 2020. Lutetium-177 prostate-specific membrane antigen (PSMA) theranostics: practical nuances and intricacies. Prostate Cancer Prostatic Dis. 23(1):38–52. 10.1038/s41391-019-0174-x.
   PubMed Web of Science ®Google Scholar
• Thang SP, Violet J, Sandhu S, Iravani A, Akhurst T, Kong G, Ravi Kumar A, Murphy DG, Williams SG, Hicks RJ, et al. 2019. Poor Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer with Low Prostate-specific Membrane Antigen (PSMA) Expression Deemed Ineligible for 177Lu-labelled PSMA Radioligand Therapy. Eur Urol Oncol. 2(6):670–676. DOI:10.1016/j.euo.2018.11.007
   PubMed Web of Science ®Google Scholar
• Violet J, Sandhu S, Iravani A, Ferdinandus J, Thang S-P, Kong G, Kumar AR, Akhurst T, Pattison D, Beaulieu A, et al. 2020. Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of 177 Lu-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate Cancer. J Nucl Med. 61(6):857–865. DOI:10.2967/jnumed.119.236414
   PubMed Web of Science ®Google Scholar
• Taïeb D, Foletti J-M, Bardiès M, Rocchi P, Hicks RJ, Haberkorn U. 2018. PSMA-Targeted Radionuclide Therapy and Salivary Gland Toxicity: why Does It Matter? J Nucl Med. 59(5):747–748. 10.2967/jnumed.118.207993.
   PubMed Web of Science ®Google Scholar
• Ahmadzadehfar H, Eppard E, Kürpig S, Fimmers R, Yordanova A, Schlenkhoff CD, Gärtner F, Rogenhofer S, Essler M. 2016. Therapeutic response and side effects of repeated radioligand therapy with 177 Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer. Oncotarget. 7(11):12477–12488. 10.18632/oncotarget.7245.
   PubMedGoogle Scholar
• Meyrick D, Gallyamov M, Sabarimurugan S, Falzone N, Lenzo N. 2021. Real-World Data Analysis of Efficacy and Survival After Lutetium-177 Labelled PSMA Ligand Therapy in Metastatic Castration-Resistant Prostate Cancer. Target Oncol. 16(3):369–380. 10.1007/s11523-021-00801-w.
   PubMed Web of Science ®Google Scholar
• Gafita A, Fendler WP, Wang H, Sandhu SK, Weber M, Esfandiari R, Czernin J, Rathke H, Rauscher I, Tauber R, et al. 2020. Efficacy and safety of 177 Lu-PSMA radionuclide treatment in patients with diffuse bone marrow involvement: a multicenter retrospective study. J Clin Oncol. 38(15_suppl):e17543–e. DOI:10.1200/JCO.2020.38.15_suppl.e17543
   Web of Science ®Google Scholar
• Kesavan M, Turner JH. 2016. Myelotoxicity of Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors: a Decade of Experience. Cancer Biother Radiopharm. 31(6):189–198. 10.1089/cbr.2016.2035.
   PubMed Web of Science ®Google Scholar
• Bergsma H, Van Lom K, Mhgp R, Konijnenberg M, Blblr K, Teunissen JJM, De Herder WW, Krenning EP, Kwekkeboom DJ. 2018. Persistent Hematologic Dysfunction after Peptide Receptor Radionuclide Therapy with 177 Lu-DOTATATE: incidence, Course, and Predicting Factors in Patients with Gastroenteropancreatic Neuroendocrine Tumors. J Nucl Med. 59(3):452–458. 10.2967/jnumed.117.189712.
   PubMed Web of Science ®Google Scholar
• Groener D, Nguyen CT, Baumgarten J, Bockisch B, Davis K, Happel C, Mader N, Nguyen Ngoc C, Wichert J, Banek S, et al. 2021. Hematologic safety of 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer. EJNMMI Res. 11(1):11. DOI:10.1186/s13550-021-00805-7
   PubMed Web of Science ®Google Scholar
• Turner JH. 2020. Real-World Evidence of Clinical Outcomes in Precision Radionuclide Oncology: the NIGHTCAP Study of 177Lu-PSMA in Metastatic Prostate Cancer. Curr Pharm Des. 26(31):3799–3803. 10.2174/1381612826666200312141347.
   PubMed Web of Science ®Google Scholar
• Hehakaya C, Moors EHM, Verkooijen HM, Grobbee DE, Verburg FA, Mgeh L. 2021. 177Lu-PSMA for advanced prostate cancer: are we ready to play big? Eur J Nucl Med Mol Imaging. 48(8):2325–2328. 10.1007/s00259-020-05102-4.
   PubMed Web of Science ®Google Scholar
• Fosbøl MØ, Petersen PM, Daugaard G, Holm S, Kjaer A, Mortensen J. 2018. Impact of treatment delay in Radium-223 therapy of metastatic castration-resistant prostate cancer patients. Ann Nucl Med. 32(1):16–21. 10.1007/s12149-017-1212-1.
   PubMed Web of Science ®Google Scholar